Erythropoietin augments the cytokine response to acute endotoxin-induced inflammation in humans

Cytokine

Volumn 45, Issue 3, 2009, Pages 154-157

  Hojman, Pernille ^a   Taudorf, Sarah ^a   Lundby, Carsten ^a,b   Pedersen, Bente Klarlund ^a  

^a Rigshospitalet   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

EPO; Interleukin 10; Interleukin 6; Lipopolysaccharide; Tumor necrosis factor

Indexed keywords

ENDOTOXIN; ERYTHROPOIETIN; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD LEVEL; BODY WEIGHT; CONCENTRATION (PARAMETERS); CYTOKINE RELEASE; ESCHERICHIA COLI; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; INFLAMMATION; MALE; MEASUREMENT; MEDIATOR RELEASE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; CYTOKINES; ENDOTOXINS; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-10; INTERLEUKIN-6; LYMPHOCYTE COUNT; MALE; NEUTROPHILS; TUMOR NECROSIS FACTOR-ALPHA;

ESCHERICHIA COLI;

EID: 60649091081     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2008.12.005     Document Type: Article

References (20)

1. Konstantinopoulos P.A., Karamouzis M.V., and Papavassiliou A.G. Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: time to reach the full therapeutic potential of erythropoietin. Biochim Biophys Acta 1776 (2007) 1-9
2. Lipsic E., Schoemaker R.G., van der Meer P., Voors A.A., van Veldhuisen D.J., and van Gilst W.H. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol 48 (2006) 2161-2167
3. Li Y.W., Takemura G., Okada H., Miyata S., Maruyama R., Li L., et al. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res 71 (2006) 684-694
4. van der Meer P., Lipsic E., Henning R.H., Boddeus K., van der Velden J., Voors A.A., et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 46 (2005) 125-133
5. Brines M., and Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 6 (2005) 484-494
6. Bailey D.M., Robach P., Thomsen J.J., and Lundby C. Erythropoietin depletes iron stores: antioxidant neuroprotection for ischemic stroke?. Stroke 37 (2006) 2453
7. Li Y., Lu Z., Keogh C.L., Yu S.P., and Wei L. Erythropoietin-induced neurovascular protection, angiogenesis, and cerebral blood flow restoration after focal ischemia in mice. J Cereb Blood Flow Metab 27 (2006) 1043-1054
8. Mitra A., Bansal S., Wang W., Falk S., Zolty E., and Schrier R.W. Erythropoietin ameliorates renal dysfunction during endotoxaemia. Nephrol Dial Transplant 22 (2007) 2349-2353
9. Le Minh K., Klemm K., Abshagen K., Eipel C., Menger M.D., and Vollmar B. Attenuation of inflammation and apoptosis by pre- and posttreatment of darbepoetin-alpha in acute liver failure of mice. Am J Pathol 170 (2007) 1954-1963
10. Kumral A., Baskin H., Yesilirmak D.C., Ergur B.U., Aykan S., Genc S., et al. Erythropoietin attenuates lipopolysaccharide-induced white matter injury in the neonatal rat brain. Neonatology 92 (2007) 269-278
11. Taudorf S., Krabbe K.S., Berg R.M.G., Pedersen B.K., and Moller K. Human models of low-grade inflammation: bolus versus continuous infusion of endotoxin. Clin Vaccine Immunol 14 (2007) 250-255
12. Santos A.A., and Wilmore D.W. The systemic inflammatory response: perspective of human endotoxemia. Shock 6 (1996) S50-S56
13. Moore K.W., Ogarra A., Malefyt R.D., Vieira P., and Mosmann T.R. Interleukin-10. Annu Rev Immunol 11 (1993) 165-190
14. Bryl E., Mysliwska J., Debska-Slizien A., Rachon D., Bullo B., Lizakowski S., et al. The influence of recombinant human erythropoietin on tumor necrosis factor alpha and interleukin-10 production by whole blood cell cultures in hemodialysis patients. Artif Organs 22 (1998) 177-181
15. Lipsic E., van der Meer P., Henning R.H., Suurmeijler A.J., Boddeus K.M., van Veldhuisen D.J., et al. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol 44 (2004) 473-479
16. van der Meer P., Lipsic E., Henning R.H., de Boer R.A., Suurmeijer A.J., van Veldhuisen D.J., et al. Erythropoietin improves left ventricular and coronary flow in an experimental model of ischemia-reperfusion injury. Eur J Heart Fail 6 (2004) 853-859
17. Sharples E.J., Patel N., Brown P., Stewart K., Mota-Philipe H., Sheaff M., et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 15 (2004) 2115-2124
18. Chattopadhyay A., Das Choudhury T., Bandyopadhyay D., and Datta A.G. Protective effect of erythropoietin on the oxidative damage of erythrocyte membrane by hydroxyl radical. Biochem Pharmacol 59 (2000) 419-425
19. Chakraborty M., Ghosal J., Biswas T., and Datta A.G. Effect of erythropoietin on membrane lipid-peroxidation, superoxide-dismutase, catalase, and glutathione-peroxidase of rat Rbc. Biochem Med Metab Biol 40 (1988) 8-18
20. Genc S., Akhisaroglu M., Kuralay F., and Genc K. Erythropoietin restores glutathione peroxidase activity in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced neurotoxicity in C57BL mice and stimulates murine astroglial glutathione peroxidase production in vitro. Neurosci Lett 321 (2002) 73-76